Earlier this year, researchers reported impressive results for a treatment that offered a potential cure for intractable cases of hepatitis C. But now, millions of patients waiting for such a breakthrough may never get it.

The story of how the promising therapy got stalled despite positive research illustrates a little-acknowledged truism in the pharmaceutical industry: Sometimes drugs die not because they don't work or are unsafe, but because they don't make business sense.

The...